DICE - DICE Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the following investor conferences:
- Guggenheim 4 th Annual Immunology and Neurology Day
Fireside chat: Tuesday, November 15, 2022 at 11:20 a.m. EST
- Stifel 2022 Healthcare Conference
Presentation: Wednesday, November 16, 2022 at 8:00 a.m. EST
- Evercore ISI 5 th Annual HealthCONx Conference
Fireside chat: Wednesday, November 30, 2022 at 3:05 p.m. EST
Live and archived webcasts of the presentations will be accessible under “News & Events” in the Investors section of the company's website for 90 days after the applicable event.
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting ?4ß7 integrin and ?Vß1/?Vß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Contacts:
Media:
Katie Engleman, 1AB
katie@1abmedia.com
Investors:
investors@dicetx.com